Astellas Pharma (4503 JP): Growth Momentum Intact in Q1; FY27 Guidance Reiterated
​Astellas Pharma sees strong revenue growth in Q1FY27, driven by strategic brands and cost optimization, reiterates FY27 guidance with positive...
123 Views
Primer: Astellas Pharma (4503 JP) - Aug 2026
Astellas is navigating a critical transition period, with its blockbuster prostate cancer drug, Xtandi, facing a patent cliff starting in 2027....
120 Views
APAC Healthcare Weekly (Sept 27) – Hansoh Pharma, Innocare, Astellas, Otsuka, Telix Pharmaceuticals
Hansoh’s risvutatug rezetecan has been included in NMPA’s Priority Review list. Elevar Therapeutics won FDA approval for Lyrfigtu for bile duct...
89 Views
Curator's Cut: Soft Commodities' Hard Truths, Pricing China's Hi-Tech & Sumitomo Pharma's Placement
​This Curator's Cut highlights supply-side risks in agri-commodities, China hard-tech IPOs, and Sumitomo Pharma's share placement. Share your topic...
345 Views
APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm
NMPA accepted Sino Bio’s NDA for bispecific ADC drug candidate. FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque...
92 Views